Home › Prostate Cancer › Wisconsin › Racine
Prostate Cancer clinical trials in Racine, WI
4 studies for Prostate Cancer are looking for participants at sites in and around Racine (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Aurora Cancer Care-Racine, Racine
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- Aurora Cancer Care-Racine, Racine
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RecruitingPhase 3
- Ascension All Saints Hospital-Spring Street-Racine, Racine
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Aurora Cancer Care-Racine, Racine
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA60 studies
- St. Louis, MO47 studies
- San Francisco, CA45 studies
- Chicago, IL45 studies
- Seattle, WA44 studies
- Philadelphia, PA44 studies
- Nashville, TN43 studies
- Baltimore, MD42 studies
- Washington, DC38 studies
Other studies in Racine
- Lung Cancer7 studies
- Non-Small Cell Lung Cancer6 studies
- Colorectal Cancer4 studies
- Breast Cancer4 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
- Bladder Cancer4 studies
- Pancreatic Cancer3 studies
- Head and Neck Squamous Cell Carcinoma3 studies
- Ovarian Cancer3 studies
- Cancer (all types)3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.